Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer

AbstractKristen rat sarcoma viral oncogene homolog (KRAS) and microsatellite instability (MSI) are prognostic markers of colorectal cancer (CRC). However, the clinical value is still not fully understood, when giving the consideration to both the molecular makers. Five hundred fifty-one patients with CRC were retrospectively assessed by determining their clinicopathological features. KRAS mutations were detected by polymerase chain reaction. MSI, a defect in the mismatch repair (MMR) system, was detected by immunohistochemistry. The prognostic value of KRAS in combination with MSI was studied. Among 551 CRC patients, mutations in KRAS codon 12 and KRAS codon 13 were detected in 34.5% and 10.5% of patients, respectively. Four hundred one tumors were randomly selected to detect for MMR proteins expression. In this analysis, 30 (7.5%) tumors that had at least 1 MMR protein loss were defined as MMR protein-deficient (MMR-D), and the remaining tumors were classed as MMR protein-intact (MMR-I). According to KRAS mutation and MSI status, CRC was classified into 4 groups: Group 1, KRAS-mutated and MMR-I; Group 2, KRAS-mutated and MMR-D; Group 3, KRAS wild and MMR-I; and Group 4, KRAS wild and MMR-D. We found that patients in Group4 had the best prognosis. In conclusion, combination status of KRAS and MSI status may be used as a prognostic biomarker for CRC patient, if validated by larger studies.

• Publication year

  2016

• Venue

  Medicine

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MD.0000000000005649PMID 27977612PMCID 5268058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic impact of mutation profiling in patients with stage II and III colon cancer

  2016cited by this paper
• Cancer statistics in China, 2015

  2016cited by this paper
• Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer *

  2016cited by this paper
• Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Association between molecular subtypes of colorectal cancer and patient survival.

  2015cited by this paper
• KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer

  2015cited by this paper
• Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer

  2015cited by this paper
• KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.

  2015cited by this paper
• Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.

  2015cited by this paper
• Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

  2015cited by this paper
• BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

  2014cited by this paper
• Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

  2014cited by this paper
• Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

  2013cited by this paper
• Kras Gene Mutation and RASSF1A, FHIT and MGMT Gene Promoter Hypermethylation: Indicators of Tumor Staging and Metastasis in Adenocarcinomatous Sporadic Colorectal Cancer in Indian Population

  2013cited by this paper
• Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer

  2013cited by this paper
• Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine

  2013cited by this paper
• The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

  2013influential reference
• KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer

  2012cited by this paper
• Microsatellite instability in colorectal cancer

  2011influential reference
• Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

  2011cited by this paper
• Mismatch repair status in sporadic colorectal cancer: Immunohistochemistry and microsatellite instability analyses

  2011cited by this paper
• Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

  2010cited by this paper
• Microsatellite instability among individuals of Hispanic origin with colorectal cancer

  2010cited by this paper
• Microsatellite instability in colorectal cancer.

  2010cited by this paper
• Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

  2010cited by this paper
• Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

  2009cited by this paper
• Microsatellite Instability Did Not Predict Individual Survival in Sporadic Stage II and III Rectal Cancer Patients

  2007cited by this paper
• Microsatellite instability and the clinicopathological features of sporadic colorectal cancer

  2001cited by this paper
• Medicine

  1907cited by this paper

• KRAS and NRAS Mutations in Relation to Microsatellite Status in Colorectal Cancer: A Single-Center Study From Romania

  2025influential citation
• Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer

  2025cites this paper
• Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques

  2024cites this paper
• Biomarkers for chemotherapy and drug resistance in the mismatch repair pathway.

  2023cites this paper
• Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value

  2023cites this paper
• Variation in KRAS/NRAS/BRAF-Mutation Status by Age, Sex, and Race/Ethnicity Among a Large Cohort of Patients with Metastatic Colorectal Cancer (mCRC)

  2023cites this paper
• Caracterización molecular de pacientes con cáncer colorrectal

  2022cites this paper
• The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study

  2022cites this paper
• BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer

  2022cites this paper
• Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis

  2021cites this paper
• Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma

  2021cites this paper
• Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS

  2021cites this paper
• Prognostic and predictive role of DNA mismatch repair status in stage II‐III colorectal cancer: A systematic review and meta‐analysis

  2020cites this paper
• High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer

  2020cites this paper
• Enhancing the landscape of colorectal cancer using targeted deep sequencing

  2020cites this paper
• Clinicopathological features of Egyptian colorectal cancer patients regarding somatic genetic mutations especially in KRAS gene and microsatellite instability status: a pilot study

  2019cites this paper
• Biomarker-guided therapy for colorectal cancer: strength in complexity

  2019cites this paper
• The Developing Story of Predictive Biomarkers in Colorectal Cancer

  2019cites this paper
• Targeting strategies for glucose metabolic pathways and T cells in colorectal cancer.

  2019cites this paper
• Prognostic and predictive biomarkers in nonmetastatic colorectal cancers.

  2018cites this paper
• Mutations of key driver genes in colorectal cancer progression and metastasis

  2018cites this paper
• Correlation between microsatellite instability and RAS gene mutation and stage III colorectal cancer

  2018cites this paper
• [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].

  2018cites this paper
• Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer

  2018cites this paper
• Mutations of key driver genes in colorectal cancer progression and metastasis

  2018cites this paper
• KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark

  2018cites this paper
• Caracterización molecular en individuos con cáncer colorrectal

  2017cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper